#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Essential thrombocythaemia Systemic sclerosis pulmonary Hepatitis D Netherton's syndrome Indolent systemic mastocytosis Endocrine ophthalmopathy Acromegaly Testicular leiomyosarcoma Vascular malformation Neuroendocrine tumour of the lung Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Fontan procedure Non-Hodgkin's lymphoma unspecified histology indolent Thrombotic microangiopathy Marginal zone lymphoma refractory More trials…

    Learn about Rare Diseases

    Osteosarcoma metastatic Basal cell naevus syndrome – Treatment Cystic fibrosis lung – Diagnostics Angelman’s syndrome – Life with Disease Retinitis pigmentosa Erdheim-Chester disease – Trials in Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Trials in Disease Paroxysmal nocturnal haemoglobinuria – Treatment Nephrotic syndrome – Trials in Disease Bronchopulmonary dysplasia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Tobramycin Apremilast Fenofibrate Alpha-Tocopherol Gen1053 Piflufolastat (18F) Ds-2325A SODIUM TETRACHLOROPALLADATE RNMB3 Ethambutol Hydrochloride Citalopram Hydrobromide Teprotumumab Almagate Chloride Ion Pbf-999 Cx-039776 Bromocriptine Zilovertamab Vedotin 177LU-FAP-2286 Ponesimod More therapies…

    Learn about Your Condition

    Noninfective chorioretinitis Chronic hepatic failure Pancreatic fistula Malignant melanoma Liver transplant rejection Hyperparathyroidism secondary Pyelonephritis acute Rabies Nephroblastoma Eructation Lupus nephritis Fibrosarcoma Adenocarcinoma gastric Malignant peritoneal neoplasm Arthralgia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Effect of atomoxetine on learning dynamics in healthy adults: a study comparing single dose atomoxetine 40 mg with placebo

    Recruiting

    2 1 1
    Investigated Drugs:
    • Gelatin
    • Atomoxetine
    France

  • Study of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia

    Recruiting

    2 1
    Investigated Diseases:
    • Hypersomnia
    Investigated Drugs:
    • Alks 2680
    Belgium Czechia France Italy The Netherlands Spain

  • Study of Dapagliflozin for Reducing Cardiovascular Events in Adults with High Blood Pressure

    Recruiting

    3 1 1
    Investigated Diseases:
    • Hypertension
    Investigated Drugs:
    • Dapagliflozin
    Austria Germany Italy Portugal Slovenia Spain

  • Study of ranolazine in patients with ST-elevation heart attack and multiple blocked coronary arteries to improve small blood vessel function

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Ranolazine
    Italy

  • Study of Mezagitamab in Adults with Primary IgA Nephropathy (Berger’s Disease) to Reduce Protein in Urine

    Recruiting

    3 1
    Austria Czechia France Germany Hungary Italy +6

  • Study of inhaled LTI-03 for safety and effectiveness in patients with Idiopathic Pulmonary Fibrosis who may be receiving standard antifibrotic therapy

    Recruiting

    2 1
    Investigated Drugs:
    • LTI-03
    Germany Poland
Previous Page
1 … 151 152 153 154 155 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!